Only six patients (6.5%) were tested for anti-MOG antibody: 2 (3%) in MS-DMDs group and 4 (16%) in CS/IS group, because measurement of anti-MOG antibody was not covered by insurance in Japan. Here, MOG is linked to myeloid sarcoma.